R R

What Is Quillivant XR?

Quillivant XR is a prescription extended-release oral suspension containing methylphenidate hydrochloride. It is a central nervous system stimulant used to treat attention-deficit/hyperactivity disorder (ADHD). Quillivant XR provides a liquid alternative to solid methylphenidate formulations and is administered once daily. The reconstituted suspension contains 25 mg of methylphenidate hydrochloride per 5 mL. It is intended for patients aged six years and older and is not recommended for younger children because of increased drug exposure and adverse reactions. Quillivant XR is a Schedule II controlled substance and requires careful prescribing, storage, and monitoring.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Quillivant XR?

Quillivant XR is a prescription extended-release oral suspension containing methylphenidate hydrochloride. It is a central nervous system stimulant used to treat attention-deficit/hyperactivity disorder (ADHD). Quillivant XR provides a liquid alternative to solid methylphenidate formulations and is administered once daily. The reconstituted suspension contains 25 mg of methylphenidate hydrochloride per 5 mL. It is intended for patients aged six years and older and is not recommended for younger children because of increased drug exposure and adverse reactions. Quillivant XR is a Schedule II controlled substance and requires careful prescribing, storage, and monitoring.

read more about quillivant xr ...

Copy this HTML:

Copy HTML Copied!

How Does Quillivant XR Work?

Quillivant XR contains methylphenidate, which increases dopamine and norepinephrine signaling in the brain by interfering with neurotransmitter reuptake. These neurotransmitters participate in pathways involved in attention, impulse control, and activity regulation. The complete mechanism responsible for methylphenidate's benefit in ADHD is not fully established. Quillivant XR uses an extended-release delivery system that combines earlier and later medication release to provide effects throughout the day. The liquid formulation does not mean it acts identically to immediate-release methylphenidate solutions. Patients switching products may require a new dose adjustment because formulations differ in their release profiles and medication exposure.

Who Can Receive Quillivant XR Treatment?

Quillivant XR is approved for ADHD and is used in patients aged six years and older. It may be prescribed when a once-daily liquid stimulant is appropriate, including for patients who have difficulty swallowing tablets or capsules. Its use is not recommended in children younger than six years because clinical studies identified higher methylphenidate exposure and an increased incidence of adverse effects, including weight loss. Before prescribing Quillivant XR, healthcare professionals assess the patient's cardiovascular history, family history of serious cardiac disease, and potential motor or vocal tics. Ongoing assessment includes ADHD symptoms, appetite, growth in children, blood pressure, and mental health.

How Should Quillivant XR Be Taken?

Quillivant XR is taken orally once daily in the morning, with or without food. The recommended starting dose for patients aged six years and older is 20 mg, equivalent to 4 mL of the reconstituted 5 mg/mL suspension. The dose may be increased weekly in increments of 10 mg to 20 mg, with daily doses above 60 mg not recommended. Shake the bottle vigorously for at least 10 seconds before every dose to distribute the medication properly. Measure doses using the supplied oral dosing dispenser rather than a household spoon. Quillivant XR must be reconstituted by the pharmacist before dispensing and should not be exchanged milligram for milligram with other methylphenidate products without medical direction.

What Are the Side Effects and Warnings of Quillivant XR?

Common adverse effects associated with methylphenidate include decreased appetite, insomnia, stomach pain, nausea, irritability, dizziness, increased heart rate, and elevated blood pressure. Quillivant XR carries a boxed warning for abuse, misuse, and addiction, including the risk of overdose and death. Serious concerns include cardiovascular events in susceptible patients, psychiatric symptoms, slowed growth in children, and peripheral circulation problems. It may also cause increased intraocular pressure or acute angle-closure glaucoma in at-risk individuals. Quillivant XR must not be taken with monoamine oxidase inhibitors or within 14 days after stopping them. Chest pain, fainting, severe behavioral changes, or sudden vision problems require medical attention.

Common Questions About Quillivant XR

Is Quillivant XR a liquid ADHD medication?

Yes. Quillivant XR is an extended-release oral suspension containing methylphenidate hydrochloride. It is taken once daily to treat ADHD.

How much methylphenidate is in Quillivant XR?

After reconstitution, Quillivant XR contains 25 mg per 5 mL, equivalent to 5 mg/mL.

Does Quillivant XR need to be shaken before use?

Yes. The bottle must be shaken vigorously for at least 10 seconds before each dose so the medication is properly distributed.

Can Quillivant XR be substituted directly for QuilliChew ER?

No. Although both contain methylphenidate, their dosage forms and release characteristics differ. Switching requires clinician-directed dosing rather than automatic milligram-for-milligram substitution.

References

DailyMed - QUILLIVANT XR (methylphenidate hydrochloride) extended-release oral suspension. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c2dc2109-44a6-4797-b04e-18761dd9d45a. Date Accessed November 3, 2026.

Methylphenidate. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK547941/. Date Accessed November 3, 2026.

Methylphenidate. MedlinePlus. https://medlineplus.gov/druginfo/meds/a682188.html. Date Accessed November 3, 2026.

Methylphenidate. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Methylphenidate. Date Accessed November 3, 2026.

Methylphenidate. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK482451/. Date Accessed November 3, 2026.